Prosecution Insights
Last updated: October 04, 2026
Application No. 18/829,439

DRIFT REDUCTION ADJUVANT COMPOSITIONS AND METHODS OF USING SAME

Non-Final OA §103§112§DP
Filed
Sep 10, 2024
Priority
Dec 30, 2016 — provisional 62/440,869 +2 more
Examiner
CABRAL, ROBERT S
Art Unit
Tech Center
Assignee
Winfield Solutions LLC
OA Round
1 (Non-Final)
63%
Grant Probability
Moderate
1-2
OA Rounds
3y 6m
Est. Remaining
95%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
542 granted / 866 resolved
+2.6% vs TC avg
Strong +32% interview lift
Without
With
+32.5%
Interview Lift
resolved cases with interview
Typical timeline
5y 6m
Avg Prosecution
28 currently pending
Career history
892
Total Applications
across all art units

Statute-Specific Performance

§101
1.9%
-38.1% vs TC avg
§103
45.0%
+5.0% vs TC avg
§102
16.7%
-23.3% vs TC avg
§112
23.6%
-16.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 866 resolved cases

Office Action

§103 §112 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-20 are pending. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-20 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Regarding claims 1 and 10, the specification fails to Likewise, in claims 9 and 20, the specification fails to describe an adjuvant composition adapted to facilitate prevention of production of droplets or ultra-coarse droplets. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-20 is/are rejected under 35 U.S.C. 103 as being unpatentable over Johnson et al. (AU 2013206347) in view of Parrish (U.S. Patent No. 8,809,234). Regarding claims 1 and 10, Johnson et al. relates to spray droplet modifier compositions. See Title. The compositions reduce the drift of the sprayed liquid and comprises a viscosity-modifying agent such as guar gum. See page 5, line 16 – page 6, line 13. Suitable oils include vegetable oils such as soya bean oil. See page 17, lines 14-16. Johnson et al. does not teach that the soya bean oil is methylated. Parrish also relates to drift reduction compositions. See Title. “Embodiments also include a non-ionic surfactants selected from the group consisting of alkyl polyoxyethylene ether, polyoxypropylene glycol, an alkyl phenol ethoxylate, an alcohol ethoxylate, a sugar ether, a glucoside alkyl ether, a sucrose ester, a sorbitan ester ethoxylate, a crop oil concentrate, morpholine amide and a block copolymer”(current claims 2 and 11). Para. [0039]. Parrish also teaches that the drift reduction composition may include “10-50% by weight or volume methylated seed oil”. Para. [0039]. Specifically, Parrish teaches “methylated soybean oil” (current claim 18). Para. [0041]. Neither reference teaches the wherein clauses of claims 1 and 10. However, these wherein clauses are not construed as positive limitation because they indicate an intended use, i.e., to be tank-mixed to form an agricultural spray. A recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. Further, since a chemical composition and its properties are inseparable, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present. In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). This same applies to the wherein clauses of claims 4-9, 13-17 and 20, because they relate to the intended use as an agricultural spray. It would have been prima facie obvious to one of ordinary skill in the art prior to the effective filing date of the invention to combine the teaches of the Johnson et al. and Parrish and arrive at the claimed invention. In this instance, one of ordinary skill in the art would find motivation to combine the references because they both teach adjuvant compositions comprising guar gum, non-ionic surfactants and oil that are useful for reducing drift of sprayed compositions. In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980) (“It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose.... [T]he idea of combining them flows logically from their having been individually taught in the prior art.”) Further, established precedent holds that it is generally obvious to add known ingredients to known compositions with the expectation of obtaining their known function. See, e.g., In re Linder, 457 F.2d 506, 507 (CCPA 1972); see also In re Dial, 326 F.2d 430,432 (CCPA 1964). In this instance, it would have been prima facie obvious to incorporate into a spray drift adjuvant formulation of Johnson et al. any of the components of a drift composition taught by Parrish so as to obtain the benefits or function that they provide. Regarding claims 3 and 12, Johnson et al. teaches that “[t]he optimum hydration range [of guar gum] occurs between pH 5 and 8.” Page 14, line 13. Thus, it would have been prima facie obvious to one of ordinary skill in the art for the composition to have a pH within this range. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP §§ 706.02(l)(1) - 706.02(l)(3) for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-13 of U.S. Patent No. 11,612,164. Although the claims at issue are not identical, they are not patentably distinct from each other because they are directed to drift reduction adjuvant composition comprising guar gum, polyoxyethylene sorbitan emulsifier and methylated soybean oil in overlapping amounts. Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-15 of U.S. Patent No. 11,678,660. Although the claims at issue are not identical, they are not patentably distinct from each other because they are directed to drift reduction adjuvant composition differing only the indication of particular amounts of the claimed ingredients. Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20 of U.S. Patent No. 12,171,221. Although the claims at issue are not identical, they are not patentably distinct from each other because they are directed to drift reduction adjuvant comprising the same ingredients and adapted to be tank-mixed to form an agricultural spray. That said, established precedent holds that it is generally obvious to add known ingredients to known compositions with the expectation of obtaining their known function. See, e.g., In re Linder, 457 F.2d 506, 507 (CCPA 1972); see also In re Dial, 326 F.2d 430,432 (CCPA 1964). Here, guar gum and polyacrylamide would be substitutable rheological modifiers. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to ROBERT S CABRAL whose telephone number is (571)270-3769. The examiner can normally be reached M-F 8 am - 5 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush can be reached at 571-272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ROBERT S CABRAL/Primary Examiner, Art Unit 1614
Read full office action

Prosecution Timeline

Sep 10, 2024
Application Filed
Aug 26, 2026
Non-Final Rejection mailed — §103, §112, §DP
Sep 23, 2026
Interview Requested

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12746208
LONG-ACTING LOW-TOXICITY NOVEL CATIONIC LIPID COMPOUNDS AND COMPOSITION THEREOF
1y 8m to grant Granted Sep 29, 2026
Patent 12746230
Anticancer Compositions
1y 4m to grant Granted Sep 29, 2026
Patent 12741037
Liver-targeted fluorescence/photoacoustic dual-modal probe for early detecting drug-induced hepatic inflammation and autoimmune hepatitis
3y 8m to grant Granted Sep 22, 2026
Patent 12734275
ALLOGENEIC IMPLANTS FOR THE TREATMENT OF CARTILAGE INJURIES
5y 5m to grant Granted Sep 15, 2026
Patent 12721913
DR5 RADIOIMMUNOTHERAPY IN THE TREATMENT OF SOLID CANCERS
3y 8m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
63%
Grant Probability
95%
With Interview (+32.5%)
5y 6m (~3y 6m remaining)
Median Time to Grant
Low
PTA Risk
Based on 866 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month